Next-Generation Sequencing (NGS) has moved from whole-genome analysis to more focused "targeted" sequencing. To do this efficiently, researchers use oligonucleotide pools as "bait" to capture specific regions of interest, such as the exome or panels of genes associated with cancer. This targeted approach reduces sequencing costs and increases the depth of coverage, allowing for the detection of rare mutations that might be missed in a broader scan.

The Oligonucleotide Pool Market is benefiting from the rise of "Liquid Biopsies" in oncology. These tests require ultra-sensitive detection of circulating tumor DNA (ctDNA) in a patient's blood. By using customized oligo pools to enrich these specific tumor-derived fragments, diagnostic labs can identify cancer recurrence months before it shows up on a traditional CT scan. The high specificity and batch-to-batch reproducibility of modern oligo pools ensure that these diagnostic tests remain accurate and reliable for long-term patient monitoring.